AzTrials
AzTrials

Acne VulgarisPhase 3GEDACNE-LTNCT07389109

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

A Phase 3 study testing N-Acetyl-GED-0507-34-LEVO gel 5% in people with Acne Vulgaris, run by PPM Services S.A. at 59 sites in 3 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The clinical trial aims to test the long term safety of a new drug for acne vulgaris. The trial is performed to answer this question "Is it safe to apply the IMP daily for up to 52 weeks?". Read more about this study

Who is it for?
Ages 9 to 50 years
Conditions the study is for
Acne Vulgaris
What is being tested?
N-Acetyl-GED-0507-34-LEVO gel 5%
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
59 sitesin 3 countries
Study dates
5 Dec 2024to Dec 2026
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 9 to 50 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Informed consent obtained* * Written informed consent, before any study-related procedure, personally signed and dated by the patient if the patient is ≥ 18 years old or signed and dated by the parents or the legal guardian(s) if the patient is ≥ 9 to < 18 years old. An additional informed assent form must be signed by patient if ≥ 9 to < 18 years old to confirm his willingness to participate in the study. If the patient becomes 18 years of age during the study, the patient must provide written informed consent at that time to continue study participation.
  • Sex and age: Male and female patients aged ≥ 9 and < 50 years. Patients who turn 50 during the pivotal study can roll over to the LT study.
  • Diagnosis at screening and baseline visits:
  • a. Patients affected by facial acne vulgaris with an Investigator's Global Assessment (IGA) score: =1 or 2 for pivotal-naïve* patients not included in pivotal 12 Week treatment studies ≥ 0 for patients completing the 12-Week treatment period according to protocol in the pivotal Phase 3 trials (NAC-GED-0507-ACN-01-23-A and NAC-GED-0507-ACN-01-23-B)
  • b. Patients affected by truncal acne (optional criteria) on areas of the trunk (shoulders, upper back and upper anterior chest) accessible for patient's self- application of study medication with a Physician Global Assessment (PGA) severity grade: =1 or 2 for pivotal-naïve* patients not included in the pivotal 12Week treatment studies ≥ 0 and < 4 for patients completing the 12-Week treatment period according to protocol in the pivotal Phase 3 trials (NAC-GED-0507-ACN-01-23-A and NAC-GED-0507-ACN-01-23-B)
  • Pivotal-naïve: Patients not rolling over from NAC-GED-0507-ACN-01-23-A and NAC-GED-0507-ACN-01-23-B. If the pivotal-naïve patient is ≥ 9 and ≤ 14 years old and declined participation to pivotal Phase 3 study, a 12-week period should run before inclusion in the present study. During the 12-week period the patients will be allowed to follow their doctor's instructions regarding treatment of acne.
Show all 10Show fewer
  • Full comprehension Patients and their parents/legal guardian(s) (for < 18 years old patients) can comprehend the whole nature and purpose of the study, including possible risks and side effects, and are able to cooperate with the Investigator and to comply with the requirements of the entire study.
  • Contraception and fertility: Women of childbearing potential must be using an effective contraception method during the entire duration of the study. Effective contraception methods are those considered at least "acceptable" according to CTFG Recommendations. A prior stable treatment period is required for the following reliable methods of contraception:
  • Hormonal oral, implantable, transdermal, or injectable contraceptives must be stable for at least 6 months before the screening visit
  • A non-hormonal intrauterine device (IUD) must be started at least 2 months before the screening visit.

Who cannot join

  • Acne:
  • Patients with generalized or localized acne forms other than acne vulgaris, e.g., acne conglobata, acne fulminans, acne rosacea, secondary acne (chloracne, drug-induced acne, etc), nodule-cystic acne
  • Patients with acne requiring systemic treatment.
  • Beard and facial/body hair, tattoos:
  • Patients with a beard or who intend to grow a beard and/or to perform a facial tattoo during the study
  • Patients with facial hair or facial tattoos that could interfere with study assessments in the investigator's opinion
Show all 27Show fewer
  • For patients with truncal acne: body hair, tattoos (or who intend to perform them) on the shoulders, upper back or upper anterior chest accessible to self-application of study medication by the patient (evaluable area) that may interfere with the study assessments in the investigator's opinion.
  • Skin diseases: Patients with other active skin diseases (e.g., urticaria, atopic dermatitis, sunburn, seborrheic dermatitis, perioral dermatitis, rosacea, skin malignancies) or active skin infections in the facial or truncal region (bacterial, fungal, or viral) or any other facial or truncal disease or condition that might interfere with the evaluation of acne or place the patient at unacceptable risk.
  • Allergy: Known or suspected hypersensitivity to any active or inactive ingredient in the study medication. Patients with a history of an allergic reaction or significant sensitivity to the formulations' ingredients.
  • Topical therapies: Patients who are currently using, plan to use during the study, or discontinued less than 4 weeks before study baseline the use of prescribed or over-the-counter topical therapies for the treatment of acne, including but not limited to: corticosteroids, antibiotics, azelaic acid, benzoyl peroxide, salicylates, α-hydroxy/glycolic acid, any other topical cosmetic therapy for acne and retinoids on the face/trunk.
  • Topical skin care products and procedures: Patients who are currently using, plan to use during the study, or discontinued less than 4 weeks before study baseline the use of products for facial/truncal application containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non-mild cleansers or moisturizers containing retinol, salicylic or alpha- or beta-hydroxy acids, facial/truncal procedures such as chemical peel, laser treatment, photodynamic therapy, acne surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids, dermabrasion;
  • Phototherapy: Patients who are currently using, plan to use during the study, or discontinued less than 4 weeks before study baseline phototherapy for the treatment of acne, including but not limited to: UV-A, UV-B, heliotherapy. Patients who have the need or plan to be exposed to artificial tanning devices or excessive sunlight during the study.
  • Systemic therapies: Patients who are currently using, plan to use during the study, or discontinued less than 12 weeks before study baseline the use of systemic therapies for the treatment of acne, including but not limited to: antibiotics, isotretinoin. Other systemic therapy that could affect the patient's acne (i.e., anabolics, lithium, EGRF inhibitors, iodides, systemic corticosteroids - except inhaled corticosteroids or intrathecal corticosteroids - or other immunosuppressants), in the opinion of the investigator.
  • Known systemic diseases that can lead to acneiform eruptions:
  • Increased androgen production.
  • Adrenal origin: e.g., Cushing's disease, 21-hydroxylase deficiency;
  • Ovarian origin: e.g., polycystic ovarian syndrome, ovarian hyperthecosis
  • Cryptococcosis disseminated
  • Dimorphic fungal infections
  • Behçet's disease
  • Systemic lupus erythematosus (SLE).
  • Investigative studies: Participation in the evaluation of any other investigational product or device within 24 weeks before study baseline.
  • Diseases: Patients with underlying uncontrolled or unstable conditions (including but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal), which, in the Investigator's opinion, could significantly compromise the patient's safety and/or place the patient at an unacceptable risk. Any condition that in the investigator's opinion would make it unsafe for the patient to participate in the study.
  • Alcohol and other substance abuse: History of alcohol or other substance abuse within one year before screening.
  • Communication: Patient(s) and parents/legal guardian(s) (if applicable) unable to communicate or cooperate with the investigator due to e.g., language problems, impaired cerebral function, impaired mental conditions.
  • Reliability: Patients who may be unreliable for the study including patients who are unable to return for the scheduled visits.
  • Pregnancy*: Pregnant or breastfeeding women or women of childbearing potential who are planning to become pregnant during the study. *For all female patients of childbearing potential, pregnancy test result must be negative at screening.

Trial locations and contacts

59 sites in 3 countries.

59 sites in 3 countries

Poland29 sites

  • Specderm Poznanska Sp. j.

    Bialystok

  • Vitamed Galaj I Cichomski Sp. j.

    Bydgoszcz

  • DERMAPOLIS Medical Dermatology Center dr n.med. Edyta Gebska

    Chorzów

  • NZOZ Przychodnia Specjalistyczna "A-DERM-SERWIS"

    Częstochowa

  • Centrum Badan Klinicznych Pi-House Sp. z o.o.

    Gdansk

  • Uniwersyteckie Centrum Kliniczne

    Gdansk

  • Provita Sp. z o.o.

    Katowice

  • Silmedic Sp. z o.o.

    Katowice

  • Vita Longa Sp. z o.o.

    Katowice

  • Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k.

    Krakow

  • Jagiellońskie Centrum Innowacji Sp. z o.o.

    Krakow

  • Amicare Sp. z o.o. S.K.

    Lodz

  • Dermed Centrum Medyczne Sp. z o.o.

    Lodz

  • Clinical Best Solutions Sp. z o.o. S.K.

    Lublin

  • Velocity Nova Sp. z o.o.

    Lublin

  • St-Inspire Sp. z o.o.

    Mikołów

  • Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o.

    Nowa Sól

  • Etyka Osrodek Badan Klinicznych Tomasz Pesta S.K.A.

    Olsztyn

  • Labderm Essence Sp. z o.o.

    Ożarowice

  • Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.

    Poznan

  • Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie

    Rzeszów

  • Lukmed 2 Sp. z o.o.

    Siedlce

  • Centrum Zdrowia Dziecka I Rodziny Im. Jana Pawla II W Sosnowcu Sp. z o.o.

    Sosnowiec

  • Laser Clinic S.C. dr Tomasz Kochanowski dr Andrzej Królicki

    Szczecin

  • Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o.

    Szczecin

  • Etg Warszawa Sp. z o.o.

    Warsaw

  • Klinika Ambroziak Sp. z o.o.

    Warsaw

  • Royalderm Agnieszka Nawrocka

    Warsaw

  • EMC Instytut Medyczny S.A.

    Wroclaw

Other trials in Poland

Italy18 sites

  • Azienda Ospedaliero Universitaria Delle Marche

    Ancona, AN, 60126

  • Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

    Bologna

  • Azienda Ospedaliero Universitaria Policlinico G Rodolico San Marco Di Catania

    Catania

  • University Hospital Of Ferrara

    Ferrara

  • Azienda USL Toscana Centro

    Florence, FI, 50125

  • IRCCS Ospedale Policlinico San Martino

    Genova, GE, 16132

  • Universita Degli Studi Di Modena E Reggio Emilia

    Modena

  • Azienda Ospedaliera Universitaria Federico II Di Napoli

    Naples, 80131

  • Azienda Ospedaliera Di Rilievo Nazionale Antonio Cardarelli

    Naples

  • Azienda Ospedaliero-Universitaria Maggiore Della Carita

    Novara

  • Azienda Ospedaliera di Padova

    Padova

  • Azienda Ospedaliero Universitaria Parma

    Parma, PR, 43126

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, PV, 27100

  • Hospital Santa Maria Della Misericordia

    Perugia

  • Azienda USL Toscana Centro

    Prato

  • Azienda Ospedaliera Policlinico Universitario Tor Vergata

    Roma, RM, 00133

  • I.F.O. Istituti Fisioterapici Ospitalieri

    Roma, RM, 00144

  • Fondazione Luigi Maria Monti

    Roma

Other trials in Italy

Spain12 sites

  • Hospital Universitario Fundacion Alcorcon

    Alcorcón

  • Hospital De La Santa Creu I Sant Pau

    Barcelona

  • Sant Joan De Deu Barcelona Hospital

    Esplugues de Llobregat, 08950

  • Hospital Universitario Virgen De Las Nieves

    Granada

  • Futuremeds Spain S.L.

    Madrid, 28003

  • Futuremeds Spain S.L.

    Madrid

  • Hospital Universitario 12 De Octubre

    Madrid

  • Hospital Universitario Regional De Malaga

    Málaga, 29010

  • Hospital Universitario Virgen De La Victoria

    Málaga, 29010

  • Hospital Quironsalud Infanta Luisa

    Seville, 41010

  • Futuremeds Spain S.L.

    Seville, 41012

  • Instituto Medico Ricart Valencia S.L.

    Valencia

Other trials in Spain

About this study

The clinical trial aims to test the long term safety of a new drug for acne vulgaris. The trial is performed to answer this question "Is it safe to apply the IMP daily for up to 52 weeks?". The trial aims to accurately measure the safety and the effects of the new treatment (N-Acetyl-GED-0507-34-LEVO gel 5%) and to achieve this, patients will be review the drug containing the active ingredient.

Participants will:

  • Take drug every day for up to 52 weeks
  • Visit the site once every 4 weeks for checkups and tests (where applicable) for the first 3 months of treatment, then visit the site every 13 weeks approximately for checkups and tests (where applicable).
  • Record on a diary the daily/weekly applications of the study drug at home, and record any adverse events
Conditions
Acne Vulgaris
Being tested
N-Acetyl-GED-0507-34-LEVO gel 5%
Keywords
acne, acne vulgaris
Medical subject headings
Acne Vulgaris

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • N-Acetyl-GED-0507-34-LEVO gel 5%Drug

    Each patient will apply a fingertip unit of N-Acetyl-GED-0507-34-Levo 5% gel as a thin film, once daily (OD), to the entire facial skin area and the affected skin areas of the trunk accessible for self-application (i.e., shoulders, upper back, and upper anterior chest) for up to 52 consecutive weeks.

Study groups in NCT07389109
Study groupRoleWhat they receive
N-Acetyl-GED-0507-34-Levo 5% gelExperimentalNot described
Receives: Drug: N-Acetyl-GED-0507-34-LEVO gel 5%

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of AEs, TEAEs, ADRs, SAEs

    Incidence of all Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), Adverse Drug Reactions (ADRs), Serious Adverse Events (SAEs) throughout the study; with special attention to local TEAEs concerning the treated facial area (local dermal safety), and systemic TEAEs

    Measured: From enrollment to the end of treatment at 52 weeks

  2. Frequency of discontinuation of treatment due to TEAEs

    Measured: From enrollment to the end of treatment at 52 weeks

  3. Changes from baseline of systolic blood pressure during the study

    mmHg

    Measured: From enrollment to the end of treatment at 52 weeks

  4. Changes from baseline of diastolic blood pressure during the study

    mmHg

    Measured: From enrollment to the end of treatment at 52 weeks

  5. Changes from baseline of heart rate during the study

    bpm

    Measured: From enrollment to the end of treatment at 52 weeks

  6. Physical examination during the study (height)

    cm

    Measured: From enrollment to the end of treatment at 52 weeks

  7. Change from baseline of local tolerability- Application site signs/symptoms during the study

    Local tolerability will be evaluated based on the following signs and symptoms: application site non-lesional erythema, application site exfoliation, and application site dryness, stinging, burning, itching. For each sign/symptom, a severity score will be assigned using a 4-point scale from 0 = absent to 3 = severe. Of note, only a sign/symptom occurring after the first application of study medication that requires additional therapy or discontinuation of treatment or judged from the Investigator as clinically significant will be documented as a TEAE.

    Measured: From enrollment to the end of treatment at 52 weeks

  8. Assessment of overall application site irritation over the study duration

    Measured: From enrollment to the end of treatment at 52 weeks

  9. Physical examination during the study (weight)

    kg

    Measured: From enrollment to the end of treatment at 52 weeks

  10. Physical examination during the study (BMI)

    weight (kg) / [height (m)]²

    Measured: From enrollment to the end of treatment at 52 weeks

  11. Changes from baseline of RBC over the study duration

    unit of measurement 10E12/L

    Measured: From enrollment to the end of treatment at 52 weeks

  12. Changes from baseline of WBC over the study duration

    unit of measurement 10E9/L

    Measured: From enrollment to the end of treatment at 52 weeks

  13. Changes from baseline of Haematocrit over the study duration

    unit of measurement %

    Measured: From enrollment to the end of treatment at 52 weeks

  14. Changes from baseline of Haemoglobin over the study duration

    unit of measurement g/dl

    Measured: From enrollment to the end of treatment at 52 weeks

  15. Changes from baseline of MCV over the study duration

    unit of measurement fL

    Measured: From enrollment to the end of treatment at 52 weeks

  16. Changes from baseline of MCH over the study duration

    unit of measurement pg

    Measured: From enrollment to the end of treatment at 52 weeks

  17. Changes from baseline of MCHC over the study duration

    unit of measurement g/dL

    Measured: From enrollment to the end of treatment at 52 weeks

  18. Changes from baseline of Platelets over the study duration

    unit of measurement 10E9/L

    Measured: From enrollment to the end of treatment at 52 weeks

  19. Changes from baseline of neutrophils over the study duration

    unit of measurement 10E0/L

    Measured: From enrollment to the end of treatment at 52 weeks

  20. Changes from baseline of Lymphocytes over the study duration

    unit of measurement 10E9/L

    Measured: From enrollment to the end of treatment at 52 weeks

  21. Changes from baseline of Monocytes over the study duration

    unit of measurement 10E9/L

    Measured: From enrollment to the end of treatment at 52 weeks

  22. Changes from baseline of Eosinophils over the study duration

    unit of measurement 10E9/L

    Measured: From enrollment to the end of treatment at 52 weeks

  23. Changes from baseline of Basophils over the study duration

    unit of measurement 10E9/L

    Measured: From enrollment to the end of treatment at 52 weeks

  24. Changes from baseline of Differential blood count over the study duration

    unit of measurement %

    Measured: From enrollment to the end of treatment at 52 weeks

  25. Changes from baseline in AST (GOT) over the study duration

    unit of measurement U/L

    Measured: From enrollment to the end of treatment at 52 weeks

  26. Changes from baseline in ALT (GPT) over the study duration

    unit of measurement U/L

    Measured: From enrollment to the end of treatment at 52 weeks

  27. Changes from baseline in Triglycerides over the study duration

    unit of measurement mg/dl

    Measured: From enrollment to the end of treatment at 52 weeks

  28. Changes from baseline in Total cholesterol over the study duration

    unit of measurement mg/dl

    Measured: From enrollment to the end of treatment at 52 weeks

  29. Changes from baseline in HDL-C (high-density lipoprotein cholesterol) over the study duration

    unit of measurement mg/dl

    Measured: From enrollment to the end of treatment at 52 weeks

  30. Changes from baseline in LDL-C (low-density lipoprotein cholesterol) over the study duration

    unit of measurement mg/dl

    Measured: From enrollment to the end of treatment at 52 weeks

  31. Changes from baseline in Plasma glucose over the study duration

    unit of measurement mmol/L

    Measured: From enrollment to the end of treatment at 52 weeks

  32. Changes from baseline in HbA1c (glycated haemoglobin) over the study duration

    unit of measurement %

    Measured: From enrollment to the end of treatment at 52 weeks

  33. Changes from baseline in Insulinemia over the study duration

    unit of measurement μU/mL

    Measured: From enrollment to the end of treatment at 52 weeks

  34. Changes from baseline in beta-HCG over the study duration

    postive or negative

    Measured: From enrollment to the end of treatment at 52 weeks

Secondary outcomes (10)

  1. Percentage of patients who have improvement of IGA score at each time point (1, 2 points), vs baseline score (face)

    Measured: From enrollment to the end of treatment at 52 weeks

  2. The percentage change from baseline in total lesion count (inflammatory plus non-inflammatory) at each time point (face)

    Measured: From enrollment to the end of treatment at 52 weeks

  3. Absolute change from baseline in total lesion count at each time point (face)

    Measured: From enrollment to the end of treatment at 52 weeks

  4. Change from baseline in inflammatory lesion count (percentage and absolute), at each time point (face)

    Measured: From enrollment to the end of treatment at 52 weeks

  5. Change from baseline in non-inflammatory lesion count (percentage and absolute), at each time point. (face)

    Measured: From enrollment to the end of treatment at 52 weeks

  6. Percentage of patients who have improvement of PGA score at each time point (1, 2 points), vs baseline score

    Measured: From enrollment to the end of treatment at 52 weeks

  7. The percentage change from baseline in total lesion count (inflammatory plus non-inflammatory) at each time point (trunk)

    Measured: From enrollment to the end of treatment at 52 weeks

  8. Absolute change from baseline in total lesion count at each time point (trunk)

    Measured: From enrollment to the end of treatment at 52 weeks

  9. Change from baseline in inflammatory lesion count (percentage and absolute), at each time point (trunk)

    Measured: From enrollment to the end of treatment at 52 weeks

  10. Change from baseline in non-inflammatory lesion count (percentage and absolute), at each time point. (trunk)

    Measured: From enrollment to the end of treatment at 52 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2026
  2. Study start5 Dec 2024
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07389109
Sponsor's protocol ID
NAC-GED-0507-ACN-01-23-LT
Other IDs
2023-510342-24-00, 2023
Acronym
GEDACNE-LT
Status last verified
Sep 2026
First submitted
12 Jan 2026
Last updated
15 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing N-Acetyl-GED-0507-34-LEVO gel 5% in people with Acne Vulgaris, run by PPM Services S.A. at 59 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 59 sites in Poland, Italy, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of AEs, TEAEs, ADRs, SAEs (time frame: From enrollment to the end of treatment at 52 weeks). The study lists 34 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07389109.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in